Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III trial of subcutaneous cluster immunotherapy for birch pollen allergy
2024-517515-75-00Phase 3Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Jul 2025
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of birch pollen allergoid in birch pollen allergy, allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Mean Combined Symptom and Medication Score during peak birch pollen period. Started Jul 2025; status: completed.
02
Drugs
birch pollen allergoid
03
Conditions
birch pollen allergyallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2024-517515-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517515-75-00.